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Background: Pyrosequencing is a new technology and can be used for mutation tests. However, its data analysis is
a manual process and involves sophisticated algorithms. During this process, human errors may occur. A better way
of analyzing pyrosequencing data is needed in clinical diagnostic laboratory. Computer software is potentially useful
for pyrosequencing data analysis. We have developed such software, which is able to perform pyrosequencing
mutation data analysis for epidermal growth factor receptor, Kirsten rat sarcoma viral oncogene homolog and v-raf
murine sarcoma viral oncogene homolog B1. The input data for analysis includes the targeted nucleotide sequence,
common mutations in the targeted sequence, pyrosequencing dispensing order, pyrogram peak order and peak
heights. The output includes mutation type and percentage of mutant gene in the specimen.
Results: The data from 1375 pyrosequencing test results were analyzed using the software in parallel with manual
analysis. The software was able to generate correct results for all 1375 cases.
Conclusion: The software developed is a useful molecular diagnostic tool for pyrosequencing mutation data
analysis. This software can increase laboratory data analysis efficiency and reduce data analysis error rate.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1348911657684292.
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Epidermal growth factor receptor (EGFR), Kirsten rat
sarcoma viral oncogene homolog (KRAS) and v-raf mur-
ine sarcoma viral oncogene homolog B1(BRAF) are
oncogenes, which may harbor mutations. Molecular
diagnosis of these mutations is critical in making thera-
peutic decisions [1-8]. Pyrosequencing is a direct se-
quencing technology and can be used for detection of
these mutations [9-14]. In our clinical molecular diag-
nostic laboratory, pyrosequencing is used for EGFR
(codon 719, 746–753, 768, 790 and 858), KRAS (codon
12, 13 and 61) and BRAF (codon 600) mutation tests.
When compared to Sanger sequencing, pyrosequen-
cing has several advantages. First of all, it has higher
sensitivity. Sanger sequencing needs greater than 20 % of
tumor load in a specimen to render a reliable result,* Correspondence: dahui.qin@moffitt.org
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reproduction in any medium, provided the orwhile pyrosequencing can render a reliable result with
5 % tumor load. Therefore, pyrosequencing has higher
sensitivity. Second, pyrosequencing is faster than Sanger
sequencing. Third, pyrosequencing is more cost effect-
ive. One of the disadvantages of pyrosequencing is that
it can only sequence a short length of nucleotide se-
quence. The other disadvantage is that pyrosequencing
data analysis sometimes can be complex and challen-
ging. The pyrosequencing data analysis for EGFR, KRAS
and BRAF is a manual process. Pyrosequencing data
output is a pyrogram. The pyrogram consists of a series
of peaks with different peak heights, which reflect nu-
cleotide sequence in a targeted DNA segment. Several
variables need to be considered during pyrogram data
analysis. These variables include the dispensing order,
the pyrogram peak sequence, the peak heights, the wild-
type sequence of the targeted gene, the possible muta-
tions in a targeted gene, and the ratio of wildtype and
mutant genes in a given specimen. Although pyrose-
quencing data analysis is relatively straight forward forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.diagnosticpathology.org/content/7/1/56some mutations, it can be complex for other mutations.
Moreover, the ratio of wildtype and mutant gene copies
varies case by case, which further complicates the pyro-
gram data analysis. Therefore pyrosequencing data ana-
lysis is a relatively sophisticated manual process, during
which human errors can occur. We developed a com-




The pyrosequencing data from 1375 de-identified rou-
tine clinical mutation tests were analyzed, which is the
total number of pyrosequencing tests performed in our
lab from February, 2011 to December, 2011. The speci-
men DNA was extracted from unstained paraffin sec-
tions using QiaCube (Qiagen, Valencia, CA 91355) after
manual micro-dissection.
Pyrosequencing
The pyrosequencing for EGFR, KRAS and BRAF muta-
tion was performed according to manufacture instruc-
tions (Qiagen, Valencia, CA 91355, [15-17]) with some
modifications. Briefly, the DNA sequences of EGFR,
KRAS and BRAF that may contain common mutations
are selected as targeted sequences. The targeted
sequences are amplified using PCR. Each PCR product is
used as a template and is sequenced using pyrosequen-
cing. The sequencing primer is designed to complement
and hybridize to the sequence near the targeted muta-
tion and it usually is within a few nucleotides. (Table 1
for the targeted sequences in EGFR, KRAS and BRAF).
A unique dispensing order is designed for each targeted
sequence, which is determined based on the targeted se-
quence and possible mutation(s) in the targeted se-
quence. (Table 2 shows the dispensing order for the
targeted sequences in EGFR, KRAS and BRAF).Table 1 Targeted Mutations and Sequences for EGFR,
KRAS and BRAF mutations
Targeted Mutations Targeted Sequences
EGFR exon 18, codon 719 DSCTCCGGTGC
EGFR exon 19 deletions TATCAA[GGAATTAAGAGAAGC]
AACATCTCCGAAAGCCA
EGFR exon 20, Codon 768 CAGCGTGGACAACCCCCACG
EGFR exon 20, Codon 790 ATCAYG
EGFR exon 21 CKGGCCAAACDGCTGGGT
KRAS codon 12 & 13 NNTGRCGTAGGC
KRAS codon 61 (reverse sequencing) CTCDTGACCTG
BRAF codon 600 (reverse sequencing) CWCTGTAG
Note: “D” could be A, T, U, or G (but not C); “S” could be C or G; “Y” could be
C, T or U; “N” could any base; “R” could be A or G; “W”: T, U, or A.
“[GGAATTAAGAGAAGC]” indicates deletion of the sequence.During pyrosequencing, a sequence primer hybridizes
to the targeted DNA template. Polymerase uses deoxyri-
bonucleotide triphosphates (dNTPs) to synthesize a new
DNA strand starting from 3’ end of sequence primer
along the DNA template. The dNTPs are dispensed into
the reaction tube one by one according to the dispensing
order. When a dispensed dNTP is complementary to the
nucleotide in the DNA template, the dNTP is incorpo-
rated into the newly synthesized DNA strand. At the
same time, a pyrophosphate (PPi) is released. The
released PPi is converted into adenosine triphosphate
(ATP) by sulfurylase. The ATP is then used by luciferase
to convert luciferin to oxyluciferin, during which visible
light is generated in amounts that are proportional to
the amount of ATP. The visible light is then captured
and depicted as a peak in the pyrogram. In a pyrogram,
peaks are labeled as A or C or G or T based on which
dNTP is dispensed at the time. The peak height is pro-
portional to the number of complementary base(s) in
the template at the point of the dispensing.
Figure 1A is an example of an EGFR exon 21 pyrose-
quencing result. The targeted sequence is CTGGCC
AAACTGCTGGGT. The bold CTG is codon 858 and is
wildtype. During pyrosequencing, the instrument dis-
penses dNTPs one at a time in the dispensing order of
ACGTGTCACATGTC. The first dispensed dNTP is
deoxyadenosine alfa-thio triphosphate (dATPaS), which
serves as a substitute of deoxyadenosine triphosphate
(dATP). dATPaS is used as a substitute for the natural
dATP because it can be used by the DNA polymerase to
synthesize DNA, but is not recognized by the luciferase.
Since there is no complement nucleotide for adenosine
(A) at this position in the template, dATPaS is not incor-
porated and no visible light is generated. Therefore,
there is no peak at this position (dispensing position 1)
in the pyrogram (see position 1 in Figure 1A, which is
labeled as ‘A’). The second dispensed dNTP is deoxycys-
tidine triphosphate (dCTP). Since there is a complementTable 2 Targeted Mutations and Pyrosequencing
dispensing order for EGFR, KRAS and BRAF mutations
Targeted Mutations Pyrosequencing Dispensing Orders
EGFR exon 18, codon 719: CATGTCACTCGTG




EGFR exon 20, Codon 790 GATTCATCTG
EGFR exon 21 ACGTGTCACATGTC



























Figure 1 The pyrogram of EGFR exon21 mutation and software analysis result. Panel A is a pyrogram of EGFR L858R mutation. The small
peak at the dispensation position 8 (A peak) is seen in all cases with similar peak height regardless of different tumor loads, therefore it is
considered as non-specific noise. Panel B is the software data analysis of Panel A, indicating which peak or which portion of a peak is from either
wildtype or mutant gene.
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ition, dCTP is incorporated into newly synthesized DNA
strand and a C peak is generated (see position 2 in
Figure 1A, which is labeled as ‘C’). The third dispensed
dNTP is deoxyguanosine triphosphate (dGTP) and a G
peak is observed (see position 3 in Figure 1A, which is
labeled as ‘G’), indicating that there is a complement nu-
cleotide in the template. Since the wildtype EGFR exon
21 is supposed to have a thymidine (T) at this position,
the G peak observed at this position indicates that there
is a T to G mutation, which, in fact, is corresponding to
the EGFR L858R mutation.
Software development
The software was developed using Microsoft Excel and
is designed to identify common mutations in EGFR,
KRAS and BRAF respectively. The source of common
mutations is http://www.sanger.ac.uk/genetics/CGP/cos-
mic/ (up to 6-6-2011). A portion of the test information
is built into the software, which includes the targeted
nucleotide sequence, common mutations and pyrose-
quencing dispensing order. Other test information needs
to be input after testing, when test result raw data are
available. The raw data include pyrogram peak
sequences and peak heights. These data are copied and
pasted into computer for software data analysis. The
software analysis algorithm involves multiple steps,
which can be illustrated as following, using EGFRmutation as an example. Step 1 is pattern recognition.
In this step, the software compares the pyrogram peak
with the known wildtype peak pattern that has been
built into the software. This includes the comparison of
peak sequence and peak heights of the test result to that
of wildtype. If the resulted peak fits a wildtype peak pat-
tern, the software will call it wildtype. If the resulted
peak does not fit wildtype pattern, the software will
compare it to the common mutant peak patterns that
have been built into the software. If it fits one of the mu-
tant peak patterns, the software will consider this mu-
tant pattern as a candidate mutation. In the example
shown in Figure 1, the peak pattern fits the EGFR L858R
mutation. Therefore, the software will consider the
L858R mutation as the candidate mutation and will do
next step analysis. In the next step, the software will cal-
culate the percentage of the candidate mutant gene in
the specimen, using a built-in formula. In case of EGFR
exon 21 L858R mutation, the formula is as following:
[1/3 x A/B + (1-C/B) + (1-D/E)]/3x100.
“A” is the peak height of the second peak (which is la-
beled as ‘G’ at the dispensing position 3 in Figure 1).
“B” is the average peak height of the reference peaks,
each of which is resulted from a single nucleotide incorp-
oration. The reference peaks include the first peak (which
is labeled as ‘C’ at the dispensing position 2 in Figure 1),
the seventh peak (which is labeled as ‘C’ at the dispensing
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dispensing position 11), the ninth peak (which is labeled
as ‘G’ at the dispensing position 12) and the tenth peak
(which is labeled as ‘C’ at the dispensing position 14).
“C” is the peak height of the third peak (which is
labeled as ‘T’ at the dispensing position 4 in Figure 1).
“D” is the peak height of the fourth peak (which is
labeled as ‘G’ at the dispensing position 5 in Figure 1).
“E” is the peak height of the fifth peak (which is
labeled as ‘C’ at the dispensing position 7 in Figure 1).
A particular formula for each mutation is programmed
into the software since each mutation has its unique pyro-
gram peak pattern. If the calculated percentage of mutant
component is higher than 5 %, the software will call it mu-
tant. If the percentage is lower than 5 %, the software will
not call it mutant since our validated test sensitivity is set
to 5 %. The software analysis result is shown in Figure 1B.
It indicates that the second peak G is from a mutant; the
third and fourth peaks T and G are from wildtype; the rest
of the peaks represent a mixture of both mutant and wild-
type and the 55 % of the targeted nucleotide sequence in
this specimen is from the mutant gene.
The software developed as such is a working draft. The
working draft needs to be fine-tuned to accommodate
normal variations in lab tests. The fine-tuning is the
process of testing the software draft on real cases. Since
test results have normal variations, the working draft soft-
ware usually recognizes some mutations and misses
others. Therefore, the parameters in the software draft
need to be adjusted based on real case test data. For ex-
ample, we had a BRAF mutation case in the early stage ofa
Figure 2 The pyrogram of BRAF V600K mutation and software analys
the software analysis of Panel A, indicating which peak or which portion oour software development. The BRAF test pyrogram is
shown in Figure 2A. When the working draft software
was used to analyze this pyrogram, the result was positive
for BRAF V600E mutation (data not shown). However,
this specimen is actually positive for V600K mutation.
The working draft misinterpreted the result because it
failed to distinguish the subtle changes of the peak heights
in the fourth and fifth peaks (C and T) from normal varia-
tions. In this case, the peak C and T are slightly lower than
normal C and T. When this occurs together with a second
peak T, it indicates a BRAF V600K mutation. The working
draft is modified accordingly, adding peak height of C
peak as a variable. After such fine-tuning, the software is
able to recognize this case as V600K mutation (Figure 2B).
A total of 490 test results (121 for EGFR, 149 for KRAS,
and 220 for BRAF) were used during the fine-tuning
process.
Non-specific peaks (background noise and artifact) are
also present in pyrosequencing. To determine if a small
peak is artifact/non-specific peak, a cut off threshold is
needed. In this project, two times unexpected peak height
average was used as the cut off threshold. The unexpected
peaks are defined as the peaks observed at dispensing
positions where no peak is expected to be present in either
wild type or in common mutants. Using BRAF mutation
as an example (see pyrograms in Figures 2A and 3A), the
dispensing order is TCGTATCTGTAG and usually no
peak is expected at the dispensing positions 1, 3, and 6.
Any small peaks at these positions are considered as unex-
pected peaks. The heights of these unexpected peaks are
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Figure 3 The pyrogram of BRAF V600E mutation and software analysis result. Panel A is a pyrogram of BRAF V600E mutation. Panel B is
the software analysis of Panel A, indicating which peak or which portion of a peak is from either wildtype or mutant gene.
Table 3 Comparison of Manual and Software Data
Analysis Results for EGFR mutations
Positive Negative
Manual analysis 76 279
Software analysis 78 277
Positive: indicating that the specimen is positive for either exon 18, 19, 20 or
21. Negative: indicating that no EGFR mutation is identified in the targeted
sequences.
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as the cut off. Any peaks with the peak height lower than
the cut off are considered as non-specific peaks (artifact).
EGFR, BRAF and KRAS Mutation Test Analysis
EGFR, BRAF and KRAS mutation tests are routine clin-
ical tests in our clinical molecular lab using pyrosequen-
cing. The raw data is manually analyzed by two lab staff
members independently before a result is issued. For this
project, the software was used to independently analyze
the pyrosequencing data in parallel with manual analysis.
The manual analysis results were compared to the soft-
ware generated results.
Results
1. EGFR Mutation Data Analysis:
EGFR codon 719, 746–753, 768, 790 and 858 were
analyzed for this project. Figure 1A is a pyrogram of
exon 21 L858R mutation. The software analysis indicates
that there is a L858R mutation. 55 % of gene sequence
in this specimen is from mutated gene (Figure 1B). 355
test results have been analyzed by manual and software
analysis. The results are listed in Table 3. The software
identified 78 positive cases and the manual review iden-
tified 76 positive cases. In two occasions, exon 19deletions were overlooked by one reviewer in manual
analysis, but picked up by the software.
2. BRAF Mutation Data Analysis:
Most common BRAF mutations occur at codon 600.
Therefore, it is the targeted sequence in this assay. Dif-
ferent mutation variants have been reported at this
codon, e.g. V600E, V600K and V600R. The sequence to
be analyzed is ACAGTG in wild type. The bold GTG is
codon 600. Since the sequencing primer is a reverse se-
quencing primer, the actual sequence that is analyzed is
the reverse and complement of ACAGTG, hence
CACTGT. The resulted pyrogram is seen in Figure 3A
indicating a V600E mutation. The software analysis re-
sult in Figure 3B reaches the same conclusion. 613 test
results were analyzed by both manual and software ana-
lysis and the results are listed in Table 4. One V600K
Table 4 Comparison of Manual and Software Data
Analysis Results for BRAF mutations
Positive Negative
Manual analysis 202 411
Software analysis 203 410
Positive: indicating that the specimen is positive for either V600E, V600K or
other codon 600 mutations. Negative: indicating that no BRAF codon 600
mutation is identified.
Table 5 Comparison of Manual and Software Data
Analysis Results for KRAS mutations
Positive Negative
Manual analysis 167 240
Software analysis 168 239
Positive: indicating that the specimen is positive for either codon 12, 13, or 61.
Negative: indicating that no KRAS mutation is identified in the targeted
sequences.
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analysis and picked up by software analysis.
3. KRAS Mutation Data Analysis:
KRAS mutations may involve codon 12, 13, and 61. Each
codon may have more than one mutation variant. Figure 4A
shows a pyrogram of the G12C mutation and Figure 4B is
the software analysis result of the same case, indicating the
G12C mutation with 47 % targeted sequence containing
mutated gene in this specimen. 407 test results were ana-
lyzed by both manual and software analysis and the results
are listed in Table 5. One mutation (G13D) was overlooked
by the first round of manual analysis and picked up by soft-
ware analysis.
Among a total of 1375 tests analyzed, one-reviewer’s
manual analysis identified 347 positive results and 1028
negative results. The software identified 351 positive
results and 1024 negative results, which was confirmed
by a second reviewer. When the manual analysis resulta
Figure 4 The pyrogram of KRAS G12V mutation and software analysi
software analysis of Panel A, indicating which peak or which portion of a pis compared with software analysis result, Chi square
equals 0.061 and the two-tailed p value equals 0.8046.
The software may serve as a useful tool for quality con-
trol purpose while the difference between the two detec-
tion rates are of no statistic significance.
Discussion
The manual analysis of pyrosequencing data sometimes
is a complex process. Human error can occur during
data analysis. The main errors in manual analysis occur
in three aspects. The first is due to the complexity of
some mutations. Among the tests that are performed in
our lab, EGFR exon 19 mutations are the most complex.
The mutations in EGFR exon 19 are usually deletions
and there are many different deletions. Ten of these
deletions are more common than others. Each deletion
will generate a unique pyrogram pattern with different
peaks reflecting nucleotide sequence. Both wild type and
mutant nucleotide sequence may contribute to a certain






















s result. Panel A is a pyrogram of KRAS G12V mutation. Panel B is the
eak is from either wildtype or mutant gene.
MUT T A T C AA GG AA  CC G AAA G  CCAA C
WT T A T C AA GG AA TT AA G  A






EGFR EXON 19 747-752 DELETION
a b
Figure 5 The pyrogram of EGFR exon19 747–752 deletion and software analysis result. Panel A is a pyrogram of EGFR exon 19 deletion
between codon 747 and 752. Panel B is the software data analysis of Panel A, indicating which peak or which portion of a peak is from
either wildtype or mutant nucleotide sequence. ‘Mut’ stands for mutant sequence nucleotides that contribute to the corresponding peak.
‘WT” stands for wildtype sequence nucleotides that contribute to the corresponding peak. ‘DISP” stands for dispensing order during
pyrosequencing.
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nucleotides contributing to a certain peak may come
from different codons of wild type and mutant
sequences due to deletion. Each pyrogram pattern may
further vary due to different tumor load in each individ-
ual case. All of these variations make manual analysis
difficult. However, such complexity doesn’t pose a prob-
lem for computer software analysis. Once all of these
possible different combinations have been programmed
into the software, the computer can sort through these
possible different combinations in a rapid fashion.
Figure 5A is the pyrogram of EGFR exon 19 deletion be-
tween codon 747 and 752. Figure 5B is the software ana-
lysis result. It shows that both wildtype and mutant gene
nucleotide(s) contribute to different pyrogram peaks. The
second type of error in manual analysis is overlooking
subtle mutation changes. An example is BRAF V600K
mutation. The targeted sequence of BRAF in reverse se-
quencing is CACTGTAG. The dispensing order is
TCGTATCTGTAG (Figure 2A and 2B). In the case of the
V600K mutation, apart from mutant peak T (second
peak at dispensing position 4), the fourth peak C and
fifth peak T (at the dispensing position 7 and 8) are
lower than normal. One V600K was missed because
the second peak T distracted the data reviewer. Con-
sequently, the subtle changes in the fourth peak C
and fifth peak T were overlooked. The third type of
error in manual analysis is overlooking less common
mutant peaks. For example, in KRAS data analysis,
codon 12 mutation is more common. The datareviewer may focus on codon 12 changes and over-
look the changes in codon 13. In this project, a
KRAS G13D was missed for this reason.
The main error in computerized analysis is that sub-
optimal parameters are used to build the software for
certain mutations. For example, in the case of the
V600K mutation, the parameter for the lower fourth
peak C was initially set up as “the height of fourth peak
C is lower than 95 % of the average peak height of
equivalent normal peaks. In this case, the dispensing
order is TCGTATCTGTAG. The sixth, seventh and
ninth peaks (which are labeled as G, T and G at the dis-
pensing position of 9, 10 and 12) are used to calculate
average normal peak height. During the testing process,
it was realized that although such settings can recognize
some V600K mutations, but will occasionally misin-
terpret some V600K cases as V600E. Therefore, the
parameter was modified so that instead of using only
the fourth peak C, both the fourth peak C and fifth
peak T are used in the calculation. Moreover, instead
of using “95 % of the average”, “less than two stand-
ard deviations of the average” is used. The modified
software was tested and was able to interpret the data
correctly. It appears that standard deviation reflects
normal variation better than an arbitrary 95 %. Such
modification is part of fine-tuning process of this
software development.
Normally, two individuals will check sequencing
results to minimize the human error. In this project, we
used our software to check a total of 1375 test results
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was able to pick up 4 errors from the first round of man-
ual analysis, which were also picked up by the second re-
viewer. The results indicate that the pyrosequencing data
analysis software can be used as another layer of quality
control.
The pattern recognition concept has been used to gen-
erate software for pyrosequencing data analysis. For ex-
ample, Joakim Lundeber et al have used it for SNPs in
chromosome 9 [18]. Pyrosequencing software from Qia-
gen can provide pyrogram patterns for pure homozygous
and heterozygous results of most common mutations in
EGFR, KRAS and BRAF [15-17]. A recent software,
Pyromaker can provide simulated pyrogram patterns
with different percentages of tumor cells [19]. The soft-
ware developed in our lab is able to analyze real case
data. Real case data can be input into our software and
the output result will indicate what mutation type and
percentage of mutant gene in the specimen. Our soft-
ware also provides more extensive coverage for various
mutations in EGFR, KRAS and BRAF. For example, it
has been tailored in such a way so that it can distinguish
BRAF V600E, V600K and V600R mutations. It can also
distinguish different common variants of EGFR exon 19
deletions. Our software is also fine-tuned to accommo-
date normal variations in clinical mutation tests. Such
features of the software make it a practical tool for pyro-
sequencing data analysis of real cases.
Based on our literature search using keywords, such as
pyrosequencing, software, EGFR, KRAS and BRAF, our
software is a unique program developed for EGFR,
KRAS and BRAF pyrosequencing data analysis.
The software is designed and fine-tuned by our lab
staff members and the software can only be as good as
our lab staff members. However, the lab staff ’s know-
ledge and experiences can be built into the software dur-
ing the fine-tuning process. With such collective
wisdom, the software may perform better than one staff
member performing manual analysis. Moreover, the soft-
ware can work more consistently and objectively than a
human does, which makes it a valuable quality control
tool.
The fine-tuning is also an ongoing training process for
the software, especially for rare mutations. Our first
stage fine-tuning used the data from 490 mutation test
results. This process will continue in our lab as we
analyze more cases. The molecular lab staff serves as
trainers. Whenever a new mutation is misread by the
software, our lab will update the software to cover the
new mutation. We will adjust analysis parameters so that
the software will be able to recognize the new mutations
correctly without losing specificity. Our software is an
open system. More coverage of mutations can be added
to the software when needed.Conclusion
The pyrosequencing data analysis software developed is
a useful tool. It will tremendously increase the efficiency
and consistency of pyrosequencing data analysis.
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